¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"squamous cell carcinoma antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • basosquamous cell acanthoma
    ¹Ù´ÚÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, ±âÀúÆíÆò±Ø¼¼Æ÷Á¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • ciliated cell
    ¼¶¸ð¼¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • large cell acanthoma
    Å«¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • red cell aplasia
    ÀûÇ÷±¸¹«Çü¼º
  • sickle cell anemia
    ³´ÀûÇ÷±¸ºóÇ÷
  • subependymal giant cell astrocytoma
    ³ú½Ç¸·¹Ø°Å´ë¼¼Æ÷º°¼¼Æ÷Á¾, »óÀÇÇϰŴ뼼Æ÷º°¼¼Æ÷Á¾
  • target cell anemia
    Ç¥ÀûÀûÇ÷±¸ºóÇ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell melanoma
    dz¼±¼¼Æ÷Èæ»öÁ¾
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell epithelioma
    ¹Ù´Ú¼¼Æ÷»óÇÇÁ¾, ±âÀú¼¼Æ÷»óÇÇÁ¾
  • basal cell nevus
    ¹Ù´Ú¼¼Æ÷¸ð¹Ý, ±âÀú¼¼Æ÷¸ð¹Ý
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • beta cell
    º£Å¸¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • antigen, self
    ÀÚ°¡Ç׿ø, ÀÚ±âÇ׿ø
  • antigen, sequestered
    °Ý¸®Ç׿ø
  • antigen, serologically defined
    Ç÷ûÇÐÀû ±ÔÁ¤Ç׿ø, SDÇ׿ø
  • antigen, soluble
    ¼ö¿ë¼ºÇ׿ø
  • antigen, somatic
    ü¼¼Æ÷Ç׿ø
  • antigen, species-specific
    Á¾Æ¯ÀÌÇ׿ø
  • antigen, theta
    ¼¼Å¸¥èÇ׿ø
  • antigen, thymus-dependent
    Èä¼±ÀÇÁ¸Ç׿ø, °¡½¿»ùÀÇÁ¸Ç׿ø
  • antigen, thymus-independent
    Èä¼±ºñÀÇÁ¸Ç׿ø, °¡½¿»ùºñÀÇÁ¸Ç׿ø
  • antigen, thymus-leukemia
    Èä¼±-¹éÇ÷º´Ç׿ø, TLÇ׿ø
  • antigen, transplantation
    À̽ÄÇ׿ø
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,carcinoembryonic
    ¾ÏÁ¾¹è¾Æ¼º(äßðþÛÏä´àõ)
  • antigen,fetal
    žƼº(÷Ãä®àõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • mucinous carcinoma
    Á¡¾×¾ÏÁ¾(¡­¾ÏÁ¾).
  • mucinous carcinoma
    Á¡¾×¾ÏÁ¾(¡­äßðþ)
  • mucinous carcinoma
    Á¡¾×¾ÏÁ¾(¡­äßðþ).
  • mucinous eccrine carcinoma
    Á¡¾×¼º ÇѼ± ¾ÏÁ¾
  • mucoepidermoid carcinoma
    Á¡¾×Ç¥ÇÇ¾ç ¾ÏÁ¾.
  • mucoepidermoid carcinoma
    Á¡¾×Ç¥ÇÇ¾ç ¾ÏÁ¾(¡­øúù«åÆ äßðþ)
  • mucosal carcinoma
    Á¡¸·¾ÏÁ¾.
  • mucosal carcinoma
    Á¡¸·¾ÏÁ¾(¡­äßðþ)
  • nasopharyngeal carcinoma
    ºñÀΰ­¾Ç¼ºÁ¾¾ç
  • neuroendocrine carcinoma
    ½Å°æ ³»ºÐºñ¼º ¾Ï
  • noduloulcerative carcinoma
    °áÀý ±Ë¾ç¼º ¾Ï
  • pancreatic carcinoma
    ÃéÀå¾ÏÁ¾(õýíôäßðþ)
  • papillary carcinoma
    À¯µÎ»ó ¾ÏÁ¾(êáÔéßÒ äßðþ)
  • papillary carcinoma of thyroid
    °©»ó¼± À¯µÎ¾Ç¼ºÁ¾¾ç
  • periampullary carcinoma
    ÆØ´ëºÎÁÖº¯(ÁÖÀ§)¾ÏÁ¾(ø³ÓÞÝ»ñ²Ü«(ñ²êÌ)äßðþ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • Smooth muscle cell
    ¹Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ÆòȰ±Ù±Ù¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸íÁÖ¼¼Æ÷
  • Fusiform cell
    ¹æÃß¼¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃ߻󼼯÷
  • Supporting cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Cell of reticulum
    ¹úÁýÀ§Ä­
    [¿¾ ¿ë¾î] ¼¼¸Á¼¼Æ÷
  • Kupffer`s cell
    º°Å«Æ÷½Ä¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼¸Á³»ÇǼ¼Æ÷
  • Mitotic cell
    ºÐ¿­±â¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐ¿­±â¼¼Æ÷
  • Intermitotic cell
    ºÐ¿­»çÀ̱⼼Æ÷
    [¿¾ ¿ë¾î] °£±â¼¼Æ÷
  • Epitheloid muscle cell
    »óÇǼº±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǾç±Ù¼¼Æ÷
  • Chromophilic cell
    »ö¼Òµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÈ£¼º¼¼Æ÷
  • Pigment cell
    »ö¼Ò¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò¼¼Æ÷
  • Chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÇø¼º¼¼Æ÷
  • Cell inclusions
    ¼¼Æ÷Æ÷ÇÔ¹°
    [¿¾ ¿ë¾î] ¼¼Æ÷Æ÷ÇÔ¹°
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
LFA left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct...
MSA major serologic antigen; male-specific antigen; mannitol salt agar; Medical Services Administration;...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
SSAA sicca syndrome associated antigen A; Sjogren syndrome-associated antigen A; syringomyelia secondary ...
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
PCNA Proliferating Cell Nuclear Antigen
PCNA Proliferation Cell Nuclear Antigen
PCNA Proliferative cell nuclear antigen
PSCA Prostate Stem Cell Antigen
TCR T Cell Antigen Receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • cell count
    ¼¼Æ÷ ¼ö
    ´ÜÀ§ ºÎÇÇ´ç Æ÷ÇԵǾî ÀÖ´Â ¼¼Æ÷ ¼ö·Î¼­ º¸Åë ´ÜÀ§ ºÎÇÇ´ç Ç÷¾×¿¡ Æ÷ÇԵǾî ÀÖ´Â ÀûÇ÷±¸¿Í/ȤÀº ¹éÇ÷±¸¸¦ ¸»ÇÑ´Ù.
  • cell culture biocompatibility test
    ¼¼Æ÷ ¹è¾ç »ýü ÀûÇÕ¼º °Ë»ç¹ý
  • cell cycle-non specific
    ¼¼Æ÷ Áֱ⠺ñƯÀ̼º Á¦Á¦
  • cell death
    ¼¼Æ÷»ç
    ¼¼Æ÷°¡ Á׾´Â °úÁ¤¿¡¼­ »ýü ÀÛ¿ëÀÌ ¼¼Æ÷ ¼öÁØ¿¡¼­ Áß´ÜµÈ ÁöÁ¡. ¼¼Æ÷»ç´Â Á¶Á÷À̳ª Àå±â¸¦ Àå±â ÀÌ½Ä °ø¿©Ã¼·Î »ç¿ëÇÏ´Â °Í¿¡ ¾Õ¼­ ÀϾ´Ù.
  • cell differentiation
    ¼¼Æ÷ ºÐÈ­
    ¼¼Æ÷µéÀÌ Á¶Á÷ÀÇ ´Ù¾çÇÑ ±âº» ¼¼Æ÷ ´ÜÀ§·Î ¼ºÀåÇÏ´Â °Í. »óÇǼ¼Æ÷, ½Å°æ¼¼Æ÷
  • cell division
    ¼¼Æ÷ ºÐ¿­
    ÇϳªÀÇ ¼¼Æ÷°¡ µÑ ÀÌ»óÀ¸·Î ³ª´©¾îÁö´Â ÀÏ. º¸Åë ÇÙ ºÐ¿­ÀÌ ¼¼Æ÷Áú ºÐ¿­º¸´Ù ¸ÕÀú ÀϾ´Ù. ÀÌ ÇÙ ºÐ¿­Àº ´ëºÎºÐÀÇ °æ¿ì À¯»çºÐ¿­À̸ç, À¯»çºÐ¿­Àº ¿°»öüÀÇ ºÐ¹è¿Í °°Àº Áß¿äÇÑ ÀÏÀ» ÇÑ´Ù. ü¼¼Æ÷ ºÐ¿­°ú °¨¼ö ºÐ¿­ ¾çÂÊ¿¡¼­ º¸ÀδÙ. ü¼¼Æ÷ ºÐ¿­ÀÇ ÇÙ ºÐ¿­Àº Àü±â, Áß±â, Èıâ, ¸»±â·Î ³ª´©¾îÁø´Ù. ºÐ¿­ °á°ú ¸¸µé¾îÁø µþ ¼¼Æ÷µéÀº ¸ð¼¼Æ÷¿Í µ¿ÀÏÇϸç, ÇÙ³»ÀÇ À¯Àü¹°ÁúÀº Á¤È®ÇÏ°Ô º¹Á¦µÇ¾î 2°³ÀÇ µþ ¼¼Æ÷·Î ³ª´©¾îÁ® µé¾î°£´Ù. °¨¼ö ºÐ¿­Àº »ý½Ä ¼¼Æ÷¸¦ Çü¼ºÇÒ ¶§ ÀϾ´Â ºÐ¿­·Î¼­, ±× °á°ú ¿°»öüÀÇ ¼ö°¡ ü¼¼Æ÷¿¡ ºñÇÏ¿© ¹ÝÀ¸·Î °¨¼ÒÇÑ´Ù. ±×¸®°í ü¼¼Æ÷ ºÐ¿­ÀÇ ÇÙ ºÐ¿­¿¡ ¾Õ¼­ ÀÌÇü ÇÙ ºÐ¿­ÀÎ Á¦1ºÐ¿­ÀÌ Á¸ÀçÇÑ´Ù. ¼¼Æ÷ ºÐ¿­ °úÁ¤À» »ìÆìº¸¸é, ºÐ¿­¿¡¼­ ´ÙÀ½ ºÐ¿­±îÁöÀÇ ½Ã±â¸¦ °£±â ¶Ç´Â ÈÞÁö±â¶ó°í ÇÑ´Ù. ÀÌ °£±â¿¡´Â ¼¼Æ÷³»ÀÇ ¹°Áú´ë»ç³ª °íºÐÀÚ ÇÕ¼ºÀÌ ÀϾ°í, DNA µîÀÇ ¿°»öü ¹°ÁúÀÇ º¹Á¦µµ ÀϾ´Ù. ºÐ¿­ Á÷ÈÄ Çü¼ºµÈ µþ ¼¼Æ÷´Â °£±â¿¡ Á¡Â÷ Ä¿Á® ÇÙµµ 2¹è·Î ÀÚ¶õ´Ù. °£±â ±â°£Àº µ¿¹°, ½Ä¹°, Á¾, ǰÁ¾, Á¶Á÷, ±â°üÀÇ Â÷ÀÌ, ¿Âµµ, ¿µ¾ç µî¿¡ µû¶ó ´Ù¸£¸ç, ¼ö ½Ã°£ ¶Ç´Â ¼ö½Ê ½Ã°£¿¡ À̸£´Â °æ¿ì°¡ ¸¹´Ù. °£±âÀÇ ÇÙÀº ÇÙ ºÐ¿­À» ¾È ÇÒ »Ó ¹°Áú´ë»ç´Â ¿Õ¼ºÇÏ´Ù. À¯»çºÐ¿­¿¡ ÀÇÇØ ¿°»öü°¡ 2°³ÀÇ ÇÙÀ¸·Î ³ª´©¾îÁø ÈÄ ¼¼Æ÷Áú ºÐ¿­ÀÌ ÀϾ´Ù. ºÐ¿­±â¿¡ µé¾î¼­¸é ¿ì¼± ÇÙÀÌ Àü±â, Áß±â, Èıâ, ¸»±â¸¦ °ÅÃÄ µþ ¼¼Æ÷°¡ Çü¼ºµÈ´Ù. ¨ç Àü±â : ÇÙ ¾ÈÀÇ ¿°»ö»ç°¡ ³ª¼±ÇüÀ¸·Î ²¿¿© µÎ²®°í ª¾ÆÁ® ²ö ¸ð¾çÀÇ ¿°»öü°¡ µÈ´Ù. ¿°»öü´Â 2°³ÀÇ ¿°»ö ºÐü°¡ ºÙ¾î ÀÖ´Â ¸ð¾çÀ¸·Î µÇ¾î ÀÖÀ¸¸ç, µ¿½Ã¿¡ ÇÙ¸·, ÀÎÀÌ ¼Ò½ÇµÈ´Ù. °íµî½Ä¹°À» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ ¼¼Æ÷µéÀº ÇÑ ½ÖÀÇ Á߽ɸ³ÀÌ ÇÙ¸· ¹Ù±ùÂÊ¿¡ À§Ä¡ÇÑ´Ù. Á߽ɸ³Àº ¸ÕÀú ºÐ¿­ÇÑ ÈÄ À̵¿À» ½ÃÀÛÇÏ¿© ¾ç±Ø¿¡ µµ´ÞÇÑ´Ù. Áß½Éü°¡ ¾ø´Â ¼¼Æ÷¿¡¼­´Â ¾ç±ØÀ¸·ÎºÎÅÍ ¹æÃßü°¡ »ý±â±â ½ÃÀÛÇϴµ¥, À̸¦ ±Ø¸ð¶ó ÇÑ´Ù. µ¿½Ã¿¡ ¾ç±Ø ¶Ç´Â Áß½Éü¸¦ Áß½ÉÀ¸·Î ÇÏ¿© º°ºû ¸ð¾ç ¶Ç´Â ½Ç ¸ð¾ç ±¸Á¶¸¦ ÅëÆ²¾î ¼º»óü¶ó°í ÇÑ´Ù. À¯»çºÐ¿­ ±â°£ Áß Àü±â°¡ °¡Àå ±ä ½Ã°£À» Â÷ÁöÇÑ´Ù. ¨è Áß±â : ±¸ÇüÀÎ ÇÙÀÌ Å¸¿øÇüÀÌ µÇ¸ç ºñ¿°»öÁúÀº ¹æÃßÇüÀÇ ¹æÃßü¸¦ ÀÌ·ç¸é¼­ Àûµµ¸é
  • cell enclosure
    ¼¼Æ÷ ºÀÀÔü
    ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ¼¼Æ÷³»¿¡ ±èÀÚ ¾× µî¿¡ ÀÇÇØ ¿°»öµÈ °ú¸³»ó ¶Ç´Â ±× ¹ÛÀÇ Æ¯Â¡ÀÌ ÀÖ´Â ÇüŸ¦ º¸ÀÌ´Â ¼Òü. °£´ÜÈ÷ ºÀÀÔü¶ó°íµµ ÇÑ´Ù. ±¤°ßº´ µî ¹ÙÀÌ·¯½º º´À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÇ´Â ¼¼Æ÷ ºÀÀÔüÀÇ º»·¡ ÇüÅ¿¡ °üÇÑ ³íÀǰ¡ ¸¹¾ÒÀ¸³ª, Áö±ÝÀº ¹ÙÀÌ·¯½º º´ÀÇ º´¿øÃ¼ÀÓÀÌ È®ÀεǾú´Ù. ¼¼Æ÷ ºÀÀÔü¿¡´Â ¼¼Æ÷Áú³» ºÀÀÔü¿Í ¼¼Æ÷ÇÙ³» ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷Áú³» ºÀÀÔü¿¡´Â õ¿¬µÎ, ¿ìµÎÀÇ °¡¸£´Ï¿¡¸® ¼Òü, ±¤°ßº´ÀÇ ³×±×¸® ¼Òü µîÀÌ ÀÖ´Ù. À̵éÀº È£»ê¼º, ¿øÇü, ±ÕÁú ¶Ç´Â °ú¸³»ó ±¸Á¶¸¦ °¡Áø °Í°ú Æ®¶óÄÚ¸¶ÀÇ ÇÁ·Î¹Ùüũ ¼Òü µî È£¿°±â¼ºÀ¸·Î º¹ÀâÇÑ ÇüÀ» °¡Áø °ÍÀÌ ÀÖ´Ù. ¼¼Æ÷ÇÙ³» ºÀÀÔü¿¡´Â Ç츣Æä½º À¯¹ß ¹ÙÀÌ·¯½º·Î Çü¼ºµÈ ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷ ºÀÀÔü¸¦ ÇÔÀ¯ ³»¿ë¹°¿¡ µû¶ó ºÐ·ùÇϸé, ¹ÙÀÌ·¯½º°¡ ¸ðÀÎ °Í°ú ¹ÙÀÌ·¯½º ±¸¼º ¹°Áú·Î µÈ °ÍÀÌ ¸ðÀÎ °Í, ±×¸®°í ¹ÙÀÌ·¯½ºÀÇ ¼ººÐ°ú °ü·ÃÀÌ ¾ø´Â ƯÀ¯ÇÑ ´Ü¹éÁú·Î ÀÌ·ç¾îÁø °Í µî 3Á¾·ù·Î ³ª´¶´Ù. ¼¼Æ÷ ºÀÀÔüÀÇ Çü¼ºÀº ÁÖ·Î ¹ÙÀÌ·¯½ºÀÇ °¨¿°°ú °ü·ÃµÇ³ª À̿ܿ¡µµ Áß±Ý¼Ó µîÀÇ ¾àǰ Åõ¿©³ª ¼¼Æ÷´ë»ç Àå¾Ö¸¦ ÀÏÀ¸Å°´Â °Í¿¡ ÀÇÇÏ¿© ³ªÅ¸³ª±âµµ ÇÑ´Ù. ¿¹¸¦ µé¸é, ÁßÃ߽Űæ°èÀÇ ÁúȯÀÎ ÆÄŲ½¼ º´ÀÇ °æ¿ì ½Å°æ¼¼Æ÷³»¿¡¼­ ·¹ºß ¼Òü¶ó´Â ¼Òü¸¦, ¹Ì¿ÀŬ·Î´©½º °£Áú ȯÀÚÀÇ ³ú³ª ô¼öÀÇ ½Å°æ¼¼Æ÷³»¿¡¼­´Â ¹Ì¿ÀŬ·Î´©½º ¼Òü¸¦ º¼ ¼ö Àִµ¥ À̵éÀº ¸ðµÎ ¼¼Æ÷Áú³» ºÀÀÔüÀÌ´Ù.
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cell harverter
    ¼¼Æ÷ ȸ¼ö±â
    ´Ù¼öÀÇ ¼¼Æ÷ ¹è¾ç ¿ë±â¿¡¼­ µ¿½Ã¿¡ ¹è¾çµÈ ´É·üÀÌ ÁÁÀº ¼¼Æ÷¸¦ äÃëÇÏ´Â ±â±âÀÇ ÃÑĪ.
  • cell hybridization
    ¼¼Æ÷ ÇÏÀ̺긮µå Çü¼º
  • cell injury
    ¼¼Æ÷ ¼Õ»ó
  • cell interface
    ¼¼Æ÷ »çÀÌ ¸é, ¼¼Æ÷ °£¸é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
lobular carcinoma in situ <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma.
Synonym: lobular carcinoma in situ, lobular neoplasia.
(05 Mar 2000)
Lucke carcinoma <cell biology, oncology> A renal carcinoma, caused by a herpes virus, in frogs, it aroused interest because its abnormal growth appears to be dependent on a restricted temperature range. Nuclei from these cells give rise to normal frogs if transplanted into enucleated eggs, giving support to the epigenetic theories of neoplasia.
(18 Nov 1997)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen-presenting cells Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation.
(12 Dec 1998)
antigen processing Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á